Penetration of ertapenem into different pulmonary compartments of patients undergoing lung surgery

被引:33
作者
Burkhardt, O
Majcher-Peszynska, J
Borner, K
Mundkowski, R
Drewelow, B
Derendorf, H
Welte, T
机构
[1] Univ Florida, Coll Pharm, Dept Pharmaceut, Gainesville, FL 32610 USA
[2] Univ Magdeburg, Dept Pulm & Crit Care Med, D-39106 Magdeburg, Germany
[3] Hannover Med Sch, Dept Pulm Med, D-3000 Hannover, Germany
[4] Univ Rostock, Dept Clin Pharmacol, Rostock, Germany
[5] Free Univ Berlin, Dept Clin Chem & Pathobiochem, D-1000 Berlin, Germany
关键词
ertapenem; pharmacokinetics; plasma; lung tissue; ELF; alveolar cells; CAP;
D O I
10.1177/0091270005276117
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Ertapenem is approved for the treatment of community-acquired pneumonia ( CAP), but its in vivo penetration into lung tissue ( LT), epithelial lining fluid ( ELF), and alveolar cells ( AC) is unknown. Fifteen patients undergoing thoracotomy were treated with 1 g intravenously for perioperative prophylaxis. Bronchoalveolar lavage was performed 1, 3, and 5 hours after ertapenem infusion. Normal LT was sampled at the time of lung extraction. Blood was collected before and at different time points up to 24 hours after infusion. Mean concentrations of ertapenem in plasma, ELF, and AC were at 1.0 hour, 63.1, 4.06, 0.004 mg/L; at 3.0 hours, 39.7, 2.59, 0.003 mg/L; and at 5.0 hours, 27.2, 2.83, 0.007 mg/L. Mean ( range) concentration in LT was 7.60 ( 2.5 - 19.4) mg/kg tissue 1.5 to 4.5 hours after infusion. In plasma, ertapenem exhibited a C-max of 94.7 +/- 23.3 mg/L and an AUC(0-last) of 501.1 +/- 266.3 mg.h/ L. These results, combined with the reported ( MIC) 90 of most CAP bacteria, support the previously observed clinical efficacy of ertapenem in the treatment of CAP.
引用
收藏
页码:659 / 665
页数:7
相关论文
共 30 条
[1]   In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics [J].
Alhambra, A ;
Cuadros, JA ;
Cacho, J ;
Gómez-Garcés, JL ;
Alós, JI .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 (06) :1090-1094
[2]   PROPHYLACTIC AND THERAPEUTIC ACTIVITIES OF AZITHROMYCIN IN A MOUSE MODEL OF PNEUMOCOCCAL PNEUMONIA [J].
AZOULAYDUPUIS, E ;
VALLEE, E ;
BEDOS, JP ;
MUFFATJOLY, M ;
POCIDALO, JJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (06) :1024-1028
[3]  
BALDWIN DR, 1990, EUR RESPIR J, V3, P886
[4]   PULMONARY DISPOSITION OF ANTIMICROBIAL AGENTS - INVIVO OBSERVATIONS AND CLINICAL RELEVANCE [J].
BALDWIN, DR ;
HONEYBOURNE, D ;
WISE, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (06) :1176-1180
[5]   PREDICTING THE EFFICACY OF ANTIMICROBIAL AGENTS IN RESPIRATORY-INFECTIONS - IS TISSUE CONCENTRATION A VALID MEASURE [J].
BERGOGNEBEREZIN, E .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1995, 35 (03) :363-371
[6]   THERAPEUTIC EFFICACY OF CEFADROXIL AND CEPHALEXIN FOR PNEUMONIA IN A RAT TEST MODEL [J].
CHISHOLM, DR ;
DEREGIS, RG ;
BEHR, DA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1986, 30 (01) :105-109
[7]   Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men [J].
Craig, WA .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) :1-10
[8]   A review of its microbiologic, pharmacokinetic and clinical aspects [J].
Cunha, BA .
DRUGS OF TODAY, 2002, 38 (03) :195-213
[9]   In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers [J].
Fuchs, PC ;
Barry, AL ;
Brown, SD .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) :1915-1918
[10]   Treatment of complicated community-acquired infections with ertapenem, the first Group 1 carbapenem - Introduction [J].
Goldstein, EJC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 :5-6